These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

671 related articles for article (PubMed ID: 28174091)

  • 1. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
    Whittaker SR; Mallinger A; Workman P; Clarke PA
    Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
    Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
    Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L; Cao J; Lin W; Chen H; Xiong X; Ao H; Yu M; Lin J; Cui Q
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32183020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).
    Malínková V; Vylíčil J; Kryštof V
    Expert Opin Ther Pat; 2015; 25(9):953-70. PubMed ID: 26161698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
    Xie Z; Hou S; Yang X; Duan Y; Han J; Wang Q; Liao C
    J Med Chem; 2022 May; 65(9):6356-6389. PubMed ID: 35235745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
    Nandi S; Dey R; Dey S; Samadder A; Saxena AK
    Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
    Susanti NMP; Tjahjono DH
    Molecules; 2021 Jul; 26(15):. PubMed ID: 34361615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in CDK inhibitors for cancer therapy.
    Heptinstall AB; Adiyasa I; Cano C; Hardcastle IR
    Future Med Chem; 2018 Jun; 10(11):1369-1388. PubMed ID: 29846081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Bose P; Simmons GL; Grant S
    Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
    Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
    Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
    Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
    Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK7 inhibitors as anticancer drugs.
    Sava GP; Fan H; Coombes RC; Buluwela L; Ali S
    Cancer Metastasis Rev; 2020 Sep; 39(3):805-823. PubMed ID: 32385714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma.
    Liao Y; Feng Y; Shen J; Hornicek FJ; Duan Z
    Cancer Metastasis Rev; 2016 Jun; 35(2):151-63. PubMed ID: 26669603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.